Generation Bio (GBIO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

GBIO Generation Bio

Watchlist

2.180
-0.170-7.23%

Close Oct 31 16:00 ET

2.180
0.0000.00%

Post 16:02 ET

145.50MMarket Cap-912P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Bullish Generation Bio Insiders Loaded Up On US$778.9k Of Stock
Yahoo FinanceOct 30 11:06 ET
JMP Securities Maintains Generation Bio(GBIO.US) With Hold Rating
Moomoo NewsOct 23 01:31 ET · Ratings
Needham Maintains Generation Bio(GBIO.US) With Buy Rating, Maintains Target Price $10
Moomoo NewsOct 22 14:31 ET · Ratings
Generation Bio's Promising Advancements and Strategic Collaborations Drive Buy Rating
TipRanksOct 22 13:55 ET · Ratings
Express News | Generation Bio Says New Non-Human Primate Data Show Highly Selective In Vivo Delivery Of MRNA To T Cells With Cell-targeted Lipid Nanoparticle
BenzingaOct 22 07:00 ET
Generation Bio Announces the Presentation of Preclinical Data on CtLNP and IqDNA at the ESGCT 31st Annual Congress
Globe NewswireOct 22 06:59 ET

Comments

Clintzilla

Sep 19 06:58

$Generation Bio (GBIO.US)$ hmm hmm

Jaguar8

May 9 06:00

$Generation Bio (GBIO.US)$
NEWS
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
Positive
Generation Bio's presentation at the ASGCT highlights significant advancements in iqDNA technology and ctLNP delivery systems, showcasing the company's commitment to innovation in genetic medicine.
The rapid enzymatic synthesis process utilized by Generation Bio enhances the performance of iqDNA, providing a potential breakthrough in ...

Jaguar8

Apr 22 16:32

$Generation Bio (GBIO.US)$
NEWS
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Generation Bio Co. will present six abstracts at the ASGCT 27th Annual Meeting.
The abstracts will highlight preclinical data from the company's ctLNP and iqDNA platforms.
One of the presentations will focus on highly specific, in vivo delivery to T-cells with cell-targeted lipid nanoparticles.
The c...